Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 24, Issue 13, Pages 1776-1778Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458518771276
Keywords
Multiple sclerosis; alemtuzumab; sarcoidosis; immune system; immunotherapy; lymphocytes
Categories
Ask authors/readers for more resources
Background: Understanding the long-term effect of alemtuzumab on the immune system of multiple sclerosis (MS) patients is crucial. Objective: To report a case of acute sarcoidosis (Lofgren's syndrome) in a relapsing-remitting MS patient, 1.5 years after the second course of alemtuzumab treatment. Case report: Sarcoidosis was confirmed dermatohistologically, radiologically, and serologically. Analysis of the lymphocyte subpopulations showed a persistent effect of alemtuzumab treatment (CD4/CD8 ratio increased, absolute lymphocyte count of CD19-positive cells increased while CD3/4/8-positive cells were decreased). Conclusion: Our case highlights the profound effect of alemtuzumab on the immune system and its possible risk for autoimmune complications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available